J&J maintained by JMP at market perform

Johnson & Johnson Inc. was maintained by JMP Securities analyst Robert C. Faulkner at a market perform rating as the Guidant deal gives visibility on maintenance of the stent franchise through 2008, but drug patent expirations make 2008 and beyond tough years for growth. JMP said it believes the potential for zero sales growth in the out years will likely constrain share price. Shares of the New Brunswick, N.J., health care products company were up 42 cents, or 0.67%, at $63.25 on volume of 15,168,600 shares versus the three-month running average of 8,958,270 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.